SEHK:6990Biotechs
Assessing Sichuan Kelun Biotech (SEHK:6990) Valuation After Positive Phase II Sacituzumab Tirumotecan Data
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after presenting Phase II data for its TROP2 ADC sacituzumab tirumotecan with pembrolizumab in ovarian and cervical cancer at the 2026 Society of Gynecologic Oncology meeting.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The strong Phase II data appears to sit alongside building momentum in the shares, with a 30.30% year to date share price return and a 1 year total shareholder return of 82.90% at a...